Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 2
1986 2
1987 4
1988 3
1989 1
1990 1
1991 1
1992 1
1993 1
1994 1
1995 1
1996 3
1997 1
1998 6
1999 3
2000 4
2001 4
2002 3
2003 10
2004 3
2005 10
2006 6
2007 7
2008 9
2009 6
2010 7
2011 4
2012 5
2013 7
2014 7
2015 7
2016 8
2017 12
2018 15
2019 11
2020 13
2021 12
2022 13
2023 17
2024 14
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Results by year

Filters applied: . Clear all
Page 1
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T. Grothey A, et al. Among authors: shields af. N Engl J Med. 2018 Mar 29;378(13):1177-1188. doi: 10.1056/NEJMoa1713709. N Engl J Med. 2018. PMID: 29590544 Free PMC article. Clinical Trial.
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status.
André T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, Paul J, Sobrero A, Taieb J, Shields AF, Ohtsu A, Grothey A, Sargent DJ; for the IDEA Steering Committee. André T, et al. Among authors: shields af. Curr Colorectal Cancer Rep. 2013;9(3):261-269. doi: 10.1007/s11888-013-0181-6. Curr Colorectal Cancer Rep. 2013. PMID: 24032000 Free PMC article. Review.
Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection.
D'Alise AM, Brasu N, De Intinis C, Leoni G, Russo V, Langone F, Baev D, Micarelli E, Petiti L, Picelli S, Fakih M, Le DT, Overman MJ, Shields AF, Pedersen KS, Shah MA, Mukherjee S, Faivre T, Delaite P, Scarselli E, Pace L. D'Alise AM, et al. Among authors: shields af. Sci Transl Med. 2022 Aug 10;14(657):eabo7604. doi: 10.1126/scitranslmed.abo7604. Epub 2022 Aug 10. Sci Transl Med. 2022. PMID: 35947675 Free PMC article.
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
Philip PA, Azar I, Xiu J, Hall MJ, Hendifar AE, Lou E, Hwang JJ, Gong J, Feldman R, Ellis M, Stafford P, Spetzler D, Khushman MM, Sohal D, Lockhart AC, Weinberg BA, El-Deiry WS, Marshall J, Shields AF, Korn WM. Philip PA, et al. Among authors: shields af. Clin Cancer Res. 2022 Jun 13;28(12):2704-2714. doi: 10.1158/1078-0432.CCR-21-3581. Clin Cancer Res. 2022. PMID: 35302596 Free PMC article.
Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model.
Uddin MH, Al-Hallak MN, Khan HY, Aboukameel A, Li Y, Bannoura SF, Dyson G, Kim S, Mzannar Y, Azar I, Odisho T, Mohamed A, Landesman Y, Kim S, Beydoun R, Mohammad RM, Philip PA, Shields AF, Azmi AS. Uddin MH, et al. Among authors: shields af. Clin Transl Med. 2023 Dec;13(12):e1513. doi: 10.1002/ctm2.1513. Clin Transl Med. 2023. PMID: 38131168 Free PMC article.
Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
Wang J, Xiu J, Farrell A, Baca Y, Arai H, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, Shields AF, Grothey A, Weinberg BA, Marshall JL, Lou E, Khushman M, Sohal DPS, Hall MJ, Liu T, Oberley M, Spetzler D, Korn WM, Shen L, Lenz HJ. Wang J, et al. Among authors: shields af. Lancet Oncol. 2023 Feb;24(2):151-161. doi: 10.1016/S1470-2045(22)00783-5. Epub 2023 Jan 18. Lancet Oncol. 2023. PMID: 36681091 Free PMC article.
Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells.
Yankelevich M, Thakur A, Modak S, Chu R, Taub J, Martin A, Schalk D, Schienshang A, Whitaker S, Rea K, Lee DW, Liu Q, Shields AF, Cheung NV, Lum LG. Yankelevich M, et al. Among authors: shields af. J Immunother Cancer. 2024 Mar 21;12(3):e008744. doi: 10.1136/jitc-2023-008744. J Immunother Cancer. 2024. PMID: 38519053 Free PMC article. Clinical Trial.
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
Meyerhardt JA, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Bendell JC, Kumar P, Lewis D, Tan B, Bertagnolli M, Grothey A, Hochster HS, Goldberg RM, Venook A, Blanke C, O'Reilly EM, Shields AF. Meyerhardt JA, et al. Among authors: shields af. JAMA. 2021 Apr 6;325(13):1277-1286. doi: 10.1001/jama.2021.2454. JAMA. 2021. PMID: 33821899 Free PMC article. Clinical Trial.
Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
Salem ME, Bodor JN, Puccini A, Xiu J, Goldberg RM, Grothey A, Korn WM, Shields AF, Worrilow WM, Kim ES, Lenz HJ, Marshall JL, Hall MJ. Salem ME, et al. Among authors: shields af. Int J Cancer. 2020 Nov 15;147(10):2948-2956. doi: 10.1002/ijc.33115. Epub 2020 Jun 18. Int J Cancer. 2020. PMID: 32449172 Free PMC article.
225 results